Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials

Urology. 2001 Apr;57(4 Suppl 1):143-7. doi: 10.1016/s0090-4295(00)00961-4.

Abstract

Prostate cancer is a multistep process in which progression rather than initiation may be the rate-limiting step. A strong possibility is that prostatic intraepithelial neoplasia lesions that switch to angiogenic phenotype eventually progress to cancer. However, it is a challenging task to quantitate angiogenesis in preneoplastic lesions. A promising approach to measuring angiogenesis involves real-time TaqMan polymerase chain reaction to quantitate mRNAs encoding a panel of angiogenesis markers. This highly sensitive molecular technique has potential for quantitating angiogenesis in clinical settings and can be used as a high-throughput screening procedure in prostate cancer clinical trials.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / analysis
  • Disease Progression
  • Endothelial Growth Factors / metabolism
  • Gene Silencing
  • Genes, Tumor Suppressor
  • Humans
  • Lymphokines / metabolism
  • Male
  • Melanoma / metabolism
  • Mice
  • Neovascularization, Pathologic / diagnosis*
  • Neovascularization, Pathologic / metabolism
  • Phenotype
  • Polymerase Chain Reaction / methods*
  • Prostatic Intraepithelial Neoplasia / blood supply*
  • Prostatic Intraepithelial Neoplasia / genetics
  • Prostatic Intraepithelial Neoplasia / metabolism
  • Prostatic Neoplasms / blood supply*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism
  • Transplantation, Heterologous
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Biomarkers
  • Endothelial Growth Factors
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors